FDA warns GLP-1 drugs carry potential risk of rare eye condition
The U.S. Food and Drug Administration issued a warning on Monday that widely used GLP-1 medications carry a potential risk for a rare but serious eye disorder called non-arteritic anterior ischemic optic neuropathy, or NAION. Commonly referred to as an "eye stroke," the condition stems from insufficient blood flow to the optic nerve. It typically results in sudden vision loss and, in severe cases, can lead to blindness. Currently, no proven treatments exist for the condition. Following the finding, the FDA has instructed pharmaceutical manufacturers to formally notify doctors and patients about the risk.
The alert affects high-profile therapies including Novo Nordisk’s Ozempic and Wegovy, alongside Eli Lilly’s Mounjaro and Zepbound. These GLP-1 drugs have surged in popularity due to their potent weight-loss effects. However, broad real-world use among large populations frequently exposes rare adverse reactions that went undetected during initial clinical trials. By mandating explicit disclosures, regulators aim to ensure that physicians and patients are fully aware of potential complications as these medications continue to see widespread adoption.
Continue in the app — vote & join in ➔